Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

Subscribe To Our Latest Investor News

News Highlights

January 20, 2021

U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure

January 13, 2021

Bayer transforms pharma business through breakthrough innovation in healthcare

January 7, 2021

Bayer issues new senior bonds with a volume of 4 billion euros

January 7, 2021

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

Discover Bayer’s Latest Ad Hoc Releases

Explore All

1 - 10of about 601 News

1 - 10of about 601 News

January 20, 2021

Not intended for U.S. and UK Media

U.S. FDA approves vericiguat for patients with symptomatic chronic heart failure

January 13, 2021

Not intended for U.S. and UK Media - Virtual Bayer Pharma Media Day:

Bayer transforms pharma business through breakthrough innovation in healthcare

January 12, 2021

Not intended for U.S. and UK Media

U.S. FDA grants Priority Review to New Drug Application for finerenone to treat patients with chronic kidney disease and type 2 diabetes

January 11, 2021

Accelerating the Transformation of Bayer:

Supervisory Board of Bayer AG appoints Sarena Lin to Board of Management as Chief Transformation and Talent Officer

January 07, 2021

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV

January 07, 2021

NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN

Bayer issues new senior bonds with a volume of 4 billion euros

January 06, 2021

Leaps by Bayer leads USD 105 million Series B financing in Senti Bio to develop next-generation cell and gene therapies using advanced gene circuit technology platform

December 07, 2020

Not intended for U.S. and UK Media

Bayer and Atara Biotherapeutics enter strategic collaboration for next generation, mesothelin-targeted CAR-T cell therapies for solid tumors

December 02, 2020

Bayer establishes Cell and Gene Therapy Platform to accelerate pharmaceutical innovation

December 01, 2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Bayer announces placement of Elanco shares for gross proceeds of 1.6 billion U.S. dollars at completion